Henrik Ohlsson1, Marcia Vervloet, Liset van Dijk. 1. Center for Primary Health Care Research, Lund University & Region Skåne, CRC, ing 72, SUS, 205 02 Malmö, Sweden. henrik.ohlsson@med.lu.se
Abstract
PURPOSE: The Dutch national guideline for Cardiovascular Risk Management advised in 2006 initiation of statin therapy in new patients with simvastatin. After the introduction of this guideline several measures were taken to increase the prescription of simvastatin in general practice. The aim of this paper is to describe the trend and interpractice variation in the relative share of simvastatin in statin prescription over a 7-year period (2003-2009) in Dutch general practices. METHODS: Data were used from the National Registration Network of General Practice (LINH) in the Netherlands. We used multilevel logistic regression analysis with individuals nested within practices. We evaluated the variance at different time points by the intra-class correlation (ICC). RESULTS: The share of simvastatin prescriptions of all statin prescriptions increased from 40% in 2003 to 82% in 2009. While the ICC was above 20% during the periods 2005 to 2007, it decreased rapidly from 25% in 2007 to only 9% in 2009. CONCLUSION: Our results indicate that a combination of several intervention measures seems to have been successful. While it seems like the implementation of the guidelines alone had some effect, there was an additional effect when reimbursement measures were implemented. Furthermore, the practice seemed to have affected the adoption of the national CVRM guideline as the variation initially increased after the guideline implementation. By including information on both the proportion of simvastatin prescribed and interpractice variation, we achieved a more complete evaluation of how simvastatin prescription developed over time and how it was related to the different measures taken.
PURPOSE: The Dutch national guideline for Cardiovascular Risk Management advised in 2006 initiation of statin therapy in new patients with simvastatin. After the introduction of this guideline several measures were taken to increase the prescription of simvastatin in general practice. The aim of this paper is to describe the trend and interpractice variation in the relative share of simvastatin in statin prescription over a 7-year period (2003-2009) in Dutch general practices. METHODS: Data were used from the National Registration Network of General Practice (LINH) in the Netherlands. We used multilevel logistic regression analysis with individuals nested within practices. We evaluated the variance at different time points by the intra-class correlation (ICC). RESULTS: The share of simvastatin prescriptions of all statin prescriptions increased from 40% in 2003 to 82% in 2009. While the ICC was above 20% during the periods 2005 to 2007, it decreased rapidly from 25% in 2007 to only 9% in 2009. CONCLUSION: Our results indicate that a combination of several intervention measures seems to have been successful. While it seems like the implementation of the guidelines alone had some effect, there was an additional effect when reimbursement measures were implemented. Furthermore, the practice seemed to have affected the adoption of the national CVRM guideline as the variation initially increased after the guideline implementation. By including information on both the proportion of simvastatin prescribed and interpractice variation, we achieved a more complete evaluation of how simvastatin prescription developed over time and how it was related to the different measures taken.
Authors: Jaana E Martikainen; Leena K Saastamoinen; Maarit J Korhonen; Hannes Enlund; Arja Helin-Salmivaara Journal: Med Care Date: 2010-09 Impact factor: 2.983
Authors: Judith D de Jong; Peter P Groenewegen; Peter Spreeuwenberg; François Schellevis; Gert P Westert Journal: Soc Sci Med Date: 2009-10-29 Impact factor: 4.634
Authors: Christel E van Dijk; Robert A Verheij; P Spreeuwenberg; Michael J van den Berg; Peter P Groenewegen; Jozé Braspenning; Dinny H de Bakker Journal: Scand J Prim Health Care Date: 2013-01-21 Impact factor: 2.581
Authors: Tessa van Middelaar; Sophie D Ivens; Petra G van Peet; Rosalinde K E Poortvliet; Edo Richard; A Jeannette Pols; Eric P Moll van Charante Journal: BMJ Open Date: 2018-04-20 Impact factor: 2.692
Authors: Alexander Rosenberg; Christopher Fucile; Robert J White; Melissa Trayhan; Samir Farooq; Caroline M Quill; Lisa A Nelson; Samuel J Weisenthal; Kristen Bush; Martin S Zand Journal: BMC Med Inform Decis Mak Date: 2018-11-19 Impact factor: 2.796